Detail

Chr	chr11
start	1995176
end	2001470
lncRNA name	H19
entrez id	283120
hgnc id	HGNC:4713
ensg id	ENSG00000130600
refseq id	NR_002196
methods	qPCR, etc.
regulated	down-regulation
function description	Our results suggest that the combined let-7a and H19 signature is a novel prognostic factor for breast cancer patients treated with neoadjuvant chemotherapy.H19 is associated with drug-resistance in breast cancer cells.Univariate and multivariate survival analyses were conducted using the Cox proportional hazards regression method. As determined using X-tile, the optimal cutoff value for the risk score to assess progression-free survival (PFS) based on the combined signature was -0.1. Several miRNAs and lncRNAs, including let-7a and H19, provide prognostic information for many cancers.
pubmed id	29963109
year	2018
title	Combined Let-7a and H19 Signature: A Prognostic Index of Progression-Free Survival in Primary Breast Cancer Patients.
drug	V
circulating	X
survival	V